https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-05-25 15:55:112016-12-01 12:45:502013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-04-25 15:55:412016-12-01 12:46:052013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-04-25 10:56:152016-12-01 12:46:222013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-02-25 15:57:202016-12-01 12:46:532013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-25 15:59:072016-12-01 12:37:192012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-09-25 16:00:102016-12-01 12:37:512012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-07-25 16:00:392016-12-01 12:38:102012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent
